GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AveXis Inc (NAS:AVXS) » Definitions » Net Change in Cash

AveXis (AveXis) Net Change in Cash : $385.18 Mil (TTM As of Mar. 2018)


View and export this data going back to 2016. Start your Free Trial

What is AveXis Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

AveXis's Net Change in Cash for the three months ended in Mar. 2018 was $265.52 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2018 was $385.18 Mil.

AveXis Net Change in Cash Historical Data

The historical data trend for AveXis's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AveXis Net Change in Cash Chart

AveXis Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17
Net Change in Cash
-0.42 3.12 59.13 178.18 83.69

AveXis Quarterly Data
Dec13 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18
Net Change in Cash Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -35.98 213.17 -43.41 -50.09 265.52

AveXis Net Change in Cash Calculation

AveXis's Net Change in Cash for the fiscal year that ended in Dec. 2017 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-157.381+-32.047+273.115+0
=83.69

AveXis's Net Change in Cash for the quarter that ended in Mar. 2018

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-160.611+-7.921+434.053+0
=265.52

Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2018 adds up the quarterly data reported by the company within the most recent 12 months, which was $385.18 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AveXis Net Change in Cash Related Terms

Thank you for viewing the detailed overview of AveXis's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

AveXis (AveXis) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AveXis Inc (NAS:AVXS) » Definitions » Net Change in Cash
Comparable Companies
UTHR OSTO:SOBI AGIO SZSE:000661 BPMC SRPT SZSE:002007 XBRU:ABLX SHSE:600201 XKRX:128940 BOM:532523 HKSE:01548 FGEN HKSE:01530 TECH SZSE:300347 AAAP LSE:BTG LSE:ABC XKRX:086900
Traded in Other Exchanges
N/A
Address
Website
http://www.avexis.com
AveXis Inc is a United States-based clinical-stage gene therapy company. It is engaged in developing and commercializing novel treatments for patients suffering from rare and life-threatening neurological genetic diseases. Its product candidate, AVXS-101, is a gene therapy product candidate in Phase 1 clinical trial for the treatment of spinal muscular atrophy, or SMA, Type 1, the genetic cause of infant mortality. AVXS-101 is designed to deliver a fully functional human survival motor neuron gene into the nuclei of motor neurons that then generates an increase in survival motor neuron protein levels. The company believes this will result in improved motor neuron function and patient outcomes.
Executives
Sean P. Nolan director, officer: President & CEO C/O INTERMUNE, INC., 3280 BAYSHORE BLVD., BRISBANE CA 94005
Session R.a. Ii officer: Sr. VP, Corp Strategy C/O AVEXIS, INC., 2275 HALF DAY ROAD, SUITE 200, BANNOCKBURN IL 60015
Paul B Manning director, other: Former 10% Owner 200 GARRETT STREET SUITE S, CHARLOTTESVILLE VA 22902
Sukumar Nagendran officer: Sr. VP & Chief Medical Officer C/O AVEXIS, INC., 2275 HALF DAY ROAD, SUITE 160, BANNOCKBURN IL 60015
Frank Verwiel director C/O INTERMUNE, INC., 3280 BAYSHORE BLVD., BRISBANE CA 94005
James J Litalien officer: SrVP/Chief Reg&Quality Officer C/O SOMAXON PHARMACEUTICALS, INC., 3721 VALLEY CENTRE DRIVE, SUITE 500, SAN DIEGO CA 92130
Daniel G Welch director 4611 UNIVERSITY DR, 4 UNIVERSITY PLACE, DURHAM NC 27707
Rick Modi officer: Chief Business Officer C/O AVEXIS INC, 2275 HALF DAY ROAD, SUITE 200, BANNOCKBURN IL 60015
Phillip B. Donenberg officer: Chief Financial Officer C/O AVEXIS, INC., 2275 HALF DAY ROAD, SUITE 200, BANNOCKBURN IL 60015
Joao Md Siffert director 20 ENTERPRISE, SUITE 200, ALISO VIEJO CA 92656
Ag Novartis 10 percent owner LICHTSTRASSE 35, BASEL V8 CH 4056
Bong Y Koh director 7 BRYANT PARK, 23RD FLOOR, NEW YORK NY 10018
Terrence C Kearney director IN CARE OF HOSPIRA, INC., 275 NORTH FIELD DRIVE, LAKE FOREST IL 60045
Deerfield International Master Fund, L.p. 10 percent owner, other: Possible Member of 10% Group 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
James E Flynn director, 10 percent owner, other: Possible Member of 10% Group 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017